Shire Human Genetic Therapies, Inc. 4
4 · Translate Bio, Inc. · Filed Jun 30, 2020
Insider Transaction Report
Form 4
Shire Human Genetic Therapies, Inc.
10% Owner
Transactions
- Sale
Common Stock
2020-06-30$20.68/sh−6,824,992$141,140,835→ 0 total
Footnotes (2)
- [F1]This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
- [F2]These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.